Title:
NOVEL DOMINANT NEGATIVE FAS POLYPEPTIDES, CELLS COMPRISING THEREOF AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/141985
Kind Code:
A1
Abstract:
The present disclosure provides novel dominant negative Fas polypeptides comprising a first modification in the cytoplasmic domain and a second modification in the N-terminal region of human Fas. The present disclosure also provides cells comprising such novel dominant negative Fas polypeptides and an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)). Also provided are uses of the cells for treatment, e.g., for treating tumors and pathogen infections.
Inventors:
KLEBANOFF CHRISTOPHER (US)
YI FEI (US)
YI FEI (US)
Application Number:
PCT/US2021/012306
Publication Date:
July 15, 2021
Filing Date:
January 06, 2021
Export Citation:
Assignee:
MEMORIAL SLOAN KETTERING CANCER CENTER (US)
International Classes:
A61K38/00; C07K14/705; C07K14/725
Domestic Patent References:
| WO2020069508A1 | 2020-04-02 | |||
| WO2000063369A2 | 2000-10-26 |
Foreign References:
| US20180273601A1 | 2018-09-27 |
Other References:
JACKSON ET AL.: "Autoimmune Lymphoproliferative Syndrome with Defective Fas: Genotype Influences Penetrance", AM. J. HUM. GENET., vol. 64, 17 March 1999 (1999-03-17), pages 1002 - 1014, XP055701186, DOI: 10.1086/302333
YAMAMOTO ET AL.: "T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy", J. CLIN. INVEST., vol. 129, no. 4, 30 April 2019 (2019-04-30), pages 1551 - 1565, XP055632182, DOI: 10.1172/JCI121491
DHODAPKAR, M.V.: "Navigating the Fas lane to improved cellular therapy for cancer", J. CLIN. INVEST., vol. 129, no. 4, 1 April 2019 (2019-04-01), pages 1522 - 1523, XP055840609
See also references of EP 4087594A4
YAMAMOTO ET AL.: "T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy", J. CLIN. INVEST., vol. 129, no. 4, 30 April 2019 (2019-04-30), pages 1551 - 1565, XP055632182, DOI: 10.1172/JCI121491
DHODAPKAR, M.V.: "Navigating the Fas lane to improved cellular therapy for cancer", J. CLIN. INVEST., vol. 129, no. 4, 1 April 2019 (2019-04-01), pages 1522 - 1523, XP055840609
See also references of EP 4087594A4
Attorney, Agent or Firm:
LENDARIS, Steven, P. et al. (US)
Download PDF:
Previous Patent: SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF
Next Patent: CHIMERIC GMCSF-IL18 RECEPTOR
Next Patent: CHIMERIC GMCSF-IL18 RECEPTOR